O	0	6	Effect
O	7	9	of
O	10	14	home
O	14	15	-
O	15	20	based
B-intervention	21	25	high
I-intervention	25	26	-
I-intervention	26	35	intensity
I-intervention	36	44	interval
I-intervention	45	53	training
I-intervention	54	57	and
I-intervention	58	69	behavioural
I-intervention	70	82	modification
O	83	88	using
O	89	100	information
O	101	104	and
O	105	118	communication
O	119	129	technology
O	130	132	on
O	133	150	cardiorespiratory
O	151	158	fitness
O	159	162	and
O	163	171	exercise
O	172	178	habits
O	179	184	among
O	185	194	sedentary
O	195	201	breast
O	202	208	cancer
O	209	218	survivors
O	218	219	:
O	220	225	habit
O	225	226	-
O	226	227	B
O	228	233	study
O	234	242	protocol
O	243	246	for
O	247	248	a
O	249	259	randomised
O	260	270	controlled
O	271	276	trial
O	276	277	.

O	278	289	Maintaining
O	290	294	high
O	295	301	levels
O	302	304	of
O	305	313	physical
O	314	322	activity
O	323	328	helps
O	329	331	to
O	332	340	maintain
O	341	344	and
O	345	352	improve
O	353	361	physical
O	362	368	health
O	369	372	and
O	373	380	quality
O	381	383	of
O	384	388	life
O	388	389	,
O	390	393	and
O	394	399	plays
O	400	401	a
O	402	406	role
O	407	409	in
O	410	418	reducing
O	419	426	adverse
O	427	434	effects
O	435	438	due
O	439	441	to
O	442	448	cancer
O	449	459	treatments
O	459	460	.

O	461	469	Moreover
O	469	470	,
O	471	472	a
O	473	480	greater
O	481	487	degree
O	488	490	of
O	491	508	cardiorespiratory
O	509	516	fitness
O	517	519	is
O	520	530	associated
O	531	535	with
O	536	543	reduced
O	544	548	risk
O	549	551	of
O	552	555	all
O	555	556	-
O	556	561	cause
O	562	571	mortality
O	571	572	.

O	573	580	However
O	580	581	,
O	582	587	there
O	588	591	are
O	592	594	no
O	595	599	home
O	599	600	-
O	600	605	based
O	606	615	programme
O	616	619	for
O	620	629	improving
O	630	647	cardiorespiratory
O	648	655	fitness
O	656	661	using
O	662	666	body
O	667	673	weight
O	674	683	exercises
O	684	687	for
O	688	694	breast
O	695	701	cancer
O	702	711	survivors
O	711	712	.

O	713	717	This
O	718	723	study
O	724	728	will
O	729	735	assess
O	736	739	the
O	740	748	efficacy
O	749	751	of
O	752	755	the
O	756	761	newly
O	762	771	developed
O	772	777	habit
O	777	778	-
O	778	779	B
O	780	789	programme
O	790	792	on
O	793	800	maximum
O	801	807	oxygen
O	808	814	uptake
O	815	823	compared
O	824	828	with
O	829	838	treatment
O	839	841	as
O	842	847	usual
O	848	852	with
O	853	861	wearable
O	862	868	device
O	868	869	.

O	870	873	The
O	874	881	effects
O	882	884	of
O	885	889	this
O	890	899	programme
O	900	902	on
O	903	911	exercise
O	912	918	habits
O	918	919	,
O	920	925	level
O	926	928	of
O	929	937	physical
O	938	946	activity
O	946	947	,
O	948	956	physical
O	957	964	fitness
O	965	968	and
O	969	979	subjective
O	980	987	indices
O	988	992	will
O	993	997	also
O	998	1000	be
O	1001	1013	investigated
O	1013	1014	.

O	1015	1019	This
O	1020	1022	is
O	1023	1024	a
O	1025	1027	12
O	1027	1028	-
O	1028	1032	week
O	1032	1033	,
O	1034	1042	parallel
O	1042	1043	-
O	1043	1048	group
O	1048	1049	,
O	1050	1056	single
O	1056	1057	-
O	1057	1062	blind
O	1062	1063	,
O	1064	1074	randomised
O	1075	1085	controlled
O	1086	1091	trial
O	1091	1092	.

O	1093	1103	Allocation
O	1104	1108	will
O	1109	1111	be
O	1112	1119	managed
O	1120	1122	by
O	1123	1124	a
O	1125	1132	central
O	1133	1139	server
O	1140	1145	using
O	1146	1147	a
O	1148	1156	computer
O	1156	1157	-
O	1157	1166	generated
O	1167	1173	random
O	1174	1184	allocation
O	1185	1193	sequence
O	1194	1202	provided
O	1203	1205	by
O	1206	1208	an
O	1209	1220	independent
O	1221	1225	data
O	1226	1232	centre
O	1232	1233	.

O	1234	1246	Participants
O	1247	1251	will
O	1252	1254	be
O	1255	1263	assigned
O	1264	1266	to
O	1267	1270	the
O	1271	1276	habit
O	1276	1277	-
O	1277	1278	B
O	1279	1288	programme
O	1289	1290	(
O	1290	1294	high
O	1294	1295	-
O	1295	1304	intensity
O	1305	1313	interval
O	1314	1322	training
O	1322	1323	,
O	1324	1332	exercise
O	1333	1344	counselling
O	1345	1346	+
O	1347	1355	guidance
O	1355	1356	,
O	1357	1361	home
O	1361	1362	-
O	1362	1367	based
O	1368	1376	exercise
O	1377	1384	support
O	1385	1390	using
O	1391	1402	information
O	1403	1406	and
O	1407	1420	communication
O	1421	1431	technology
O	1431	1432	,
O	1433	1436	and
O	1437	1438	a
O	1439	1447	wearable
O	1448	1454	device
O	1454	1455	)
O	1456	1458	or
B-control	1459	1468	treatment
I-control	1469	1471	as
I-control	1472	1477	usual
O	1478	1482	with
O	1483	1484	a
O	1485	1493	wearable
O	1494	1500	device
O	1500	1501	.

O	1502	1510	Subjects
O	1511	1515	will
O	1516	1518	be
B-eligibility	1519	1528	sedentary
I-eligibility	1529	1534	women
O	1535	1539	aged
B-age	1540	1542	20
I-age	1542	1543	-
I-age	1543	1545	59
I-age	1546	1551	years
B-eligibility	1552	1555	who
I-eligibility	1556	1560	have
I-eligibility	1561	1569	received
I-eligibility	1570	1576	breast
I-eligibility	1577	1584	surgery
I-eligibility	1585	1587	in
I-eligibility	1588	1591	the
I-eligibility	1592	1596	past
I-eligibility	1597	1598	2
I-eligibility	1598	1599	-
I-eligibility	1599	1601	13
I-eligibility	1602	1608	months
I-eligibility	1609	1614	after
I-eligibility	1615	1618	the
I-eligibility	1619	1628	diagnosis
I-eligibility	1629	1631	of
I-eligibility	1632	1640	invasive
I-eligibility	1641	1647	breast
I-eligibility	1648	1654	cancer
I-eligibility	1655	1656	(
I-eligibility	1656	1662	stages
I-eligibility	1663	1664	I
I-eligibility	1664	1665	-
I-eligibility	1665	1668	IIa
I-eligibility	1668	1669	)
I-eligibility	1670	1673	and
I-eligibility	1674	1678	have
I-eligibility	1679	1684	never
I-eligibility	1685	1693	received
I-eligibility	1694	1706	chemotherapy
I-eligibility	1707	1713	except
I-eligibility	1714	1717	for
I-eligibility	1718	1725	hormone
I-eligibility	1726	1733	therapy
O	1733	1734	.

O	1735	1738	The
O	1739	1746	primary
O	1747	1755	endpoint
O	1756	1758	is
O	1759	1762	the
B-outcome-Measure	1763	1769	change
I-outcome-Measure	1770	1772	in
I-outcome-Measure	1773	1777	peak
I-outcome-Measure	1778	1784	oxygen
I-outcome-Measure	1785	1791	uptake
O	1792	1793	(
O	1793	1800	VO2peak
O	1800	1801	;
O	1802	1804	mL
O	1804	1805	/
O	1805	1807	kg
O	1807	1808	/
O	1808	1811	min
O	1811	1812	)
O	1813	1820	between
O	1821	1824	the
O	1825	1831	groups
O	1832	1837	after
O	1838	1840	12
O	1841	1846	weeks
O	1847	1849	of
O	1850	1862	intervention
O	1862	1863	.

O	1864	1867	The
O	1868	1873	study
O	1874	1882	protocol
O	1883	1886	was
O	1887	1895	approved
O	1896	1898	by
O	1899	1902	the
O	1903	1916	Institutional
O	1917	1923	Review
O	1924	1929	Board
O	1930	1932	of
O	1933	1936	the
O	1937	1945	National
O	1946	1952	Cancer
O	1953	1959	Center
O	1960	1965	Japan
O	1966	1968	on
O	1969	1971	28
O	1972	1980	February
O	1981	1985	2019
O	1986	1987	(
O	1987	1989	ID
O	1989	1990	:
O	1991	1995	2018
O	1995	1996	-
O	1996	1999	347
O	1999	2000	)
O	2000	2001	.

O	2002	2005	The
O	2006	2014	findings
O	2015	2019	will
O	2020	2022	be
O	2023	2035	disseminated
O	2036	2043	through
O	2044	2048	peer
O	2048	2049	-
O	2049	2057	reviewed
O	2058	2070	publications
O	2071	2074	and
O	2075	2085	conference
O	2086	2099	presentations
O	2099	2100	.

O	2101	2114	UMIN000036400
O	2114	2115	.
